<?xml version="1.0" encoding="UTF-8"?>
<html lang="en" dir="ltr" xmlns="http://www.w3.org/1999/xhtml">
 <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#"> 
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> 
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=3, minimum-scale=1, user-scalable=yes"/> 
  <meta name="type" content="article"/>
  <meta name="HW.identifier" content="/biorxiv/early/2020/04/11/2020.04.09.034942.atom"/>
  <meta name="HW.pisa" content="biorxiv;2020.04.09.034942v1"/>
  <meta name="DC.Format" content="text/html"/>
  <meta name="DC.Language" content="en"/>
  <meta name="DC.Title" content="Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of RBD mutant with lower ACE2 binding affinity"/>
  <meta name="DC.Identifier" content="10.1101/2020.04.09.034942"/>
  <meta name="DC.Date" content="2020-04-11"/>
  <meta name="DC.Publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="DC.Rights" content="Â© 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/"/>
  <meta name="DC.AccessRights" content="restricted"/>
  <meta name="DC.Description" content="Monitoring the mutation dynamics of SARS-CoV-2 is critical for the development of effective approaches to contain the pathogen. By analyzing 106 SARS-CoV-2 and 39 SARS genome sequences, we provided direct genetic evidence that SARS-CoV-2 has a much lower mutation rate than SARS. Minimum Evolution phylogeny analysis revealed the putative original status of SARS-CoV-2 and the early-stage spread history. The discrepant phylogenies for the spike protein and its receptor binding domain proved a previously reported structural rearrangement prior to the emergence of SARS-CoV-2. Despite that we found the spike glycoprotein of SARS-CoV-2 is particularly more conserved, we identified a mutation that leads to weaker receptor binding capability, which concerns a SARS-CoV-2 sample collected on 27th January 2020 from India. This represents the first report of a significant SARS-CoV-2 mutant, and raises the alarm that the ongoing vaccine development may become futile in future epidemic if more mutations were identified. ### Competing Interest Statement The authors have declared no competing interest."/>
  <meta name="DC.Contributor" content="YONG JIA"/>
  <meta name="DC.Contributor" content="Gangxu Shen"/>
  <meta name="DC.Contributor" content="Yujuan Zhang"/>
  <meta name="DC.Contributor" content="Keng-Shiang Huang"/>
  <meta name="DC.Contributor" content="Hsing-Ying Ho"/>
  <meta name="DC.Contributor" content="Wei-Shio Hor"/>
  <meta name="DC.Contributor" content="Chih-Hui Yang"/>
  <meta name="DC.Contributor" content="Chengdao Li"/>
  <meta name="DC.Contributor" content="Wei-Lung Wang"/>
  <meta name="article:published_time" content="2020-04-11"/>
  <meta name="article:section" content="New Results"/>
  <meta name="citation_title" content="Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of RBD mutant with lower ACE2 binding affinity"/>
  <meta name="citation_abstract" lang="en" content="&lt;;p&gt;;Monitoring the mutation dynamics of SARS-CoV-2 is critical for the development of effective approaches to contain the pathogen. By analyzing 106 SARS-CoV-2 and 39 SARS genome sequences, we provided direct genetic evidence that SARS-CoV-2 has a much lower mutation rate than SARS. Minimum Evolution phylogeny analysis revealed the putative original status of SARS-CoV-2 and the early-stage spread history. The discrepant phylogenies for the spike protein and its receptor binding domain proved a previously reported structural rearrangement prior to the emergence of SARS-CoV-2. Despite that we found the spike glycoprotein of SARS-CoV-2 is particularly more conserved, we identified a mutation that leads to weaker receptor binding capability, which concerns a SARS-CoV-2 sample collected on 27th January 2020 from India. This represents the first report of a significant SARS-CoV-2 mutant, and raises the alarm that the ongoing vaccine development may become futile in future epidemic if more mutations were identified.&lt;;/p&gt;;"/>
  <meta name="citation_journal_title" content="bioRxiv"/>
  <meta name="citation_publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="citation_publication_date" content="2020/01/01"/>
  <meta name="citation_mjid" content="biorxiv;2020.04.09.034942v1"/>
  <meta name="citation_id" content="2020.04.09.034942v1"/>
  <meta name="citation_public_url" content="https://www.biorxiv.org/content/10.1101/2020.04.09.034942v1"/>
  <meta name="citation_abstract_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.09.034942v1.abstract"/>
  <meta name="citation_full_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.09.034942v1.full"/>
  <meta name="citation_pdf_url" content="https://www.biorxiv.org/content/biorxiv/early/2020/04/11/2020.04.09.034942.full.pdf"/>
  <meta name="citation_doi" content="10.1101/2020.04.09.034942"/>
  <meta name="citation_section" content="New Results"/>
  <meta name="citation_firstpage" content="2020.04.09.034942"/>
  <meta name="citation_author" content="YONG JIA"/>
  <meta name="citation_author_institution" content="Murdoch University;"/>
  <meta name="citation_author_email" content="y.jia@murdoch.edu.au"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0002-0394-3966"/>
  <meta name="citation_author" content="Gangxu Shen"/>
  <meta name="citation_author_institution" content="I-Shou University;National Changhua University of Education;"/>
  <meta name="citation_author" content="Yujuan Zhang"/>
  <meta name="citation_author_institution" content="Murdoch University;"/>
  <meta name="citation_author" content="Keng-Shiang Huang"/>
  <meta name="citation_author_institution" content="I-Shou University;"/>
  <meta name="citation_author" content="Hsing-Ying Ho"/>
  <meta name="citation_author_institution" content="Guo-Yuan Clinic, Taichung, Taiwan;"/>
  <meta name="citation_author" content="Wei-Shio Hor"/>
  <meta name="citation_author_institution" content="TOPO Pharmaceutical Co., Ltd, Taichung, Taiwan;"/>
  <meta name="citation_author" content="Chih-Hui Yang"/>
  <meta name="citation_author_institution" content="I-Shou University;"/>
  <meta name="citation_author" content="Chengdao Li"/>
  <meta name="citation_author_institution" content="Murdoch University; Department of Primary Industry and Regional Development, Government of Western Australia, South Perth, WA, 6155, Australia;"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0002-9653-2700"/>
  <meta name="citation_author" content="Wei-Lung Wang"/>
  <meta name="citation_author_institution" content="National Changhua University of Education"/>
  <meta name="twitter:title" content="Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of RBD mutant with lower ACE2 binding affinity"/>
  <meta name="twitter:site" content="@biorxivpreprint"/>
  <meta name="twitter:card" content="summary"/>
  <meta name="twitter:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="twitter:description" content="Monitoring the mutation dynamics of SARS-CoV-2 is critical for the development of effective approaches to contain the pathogen. By analyzing 106 SARS-CoV-2 and 39 SARS genome sequences, we provided direct genetic evidence that SARS-CoV-2 has a much lower mutation rate than SARS. Minimum Evolution phylogeny analysis revealed the putative original status of SARS-CoV-2 and the early-stage spread history. The discrepant phylogenies for the spike protein and its receptor binding domain proved a previously reported structural rearrangement prior to the emergence of SARS-CoV-2. Despite that we found the spike glycoprotein of SARS-CoV-2 is particularly more conserved, we identified a mutation that leads to weaker receptor binding capability, which concerns a SARS-CoV-2 sample collected on 27th January 2020 from India. This represents the first report of a significant SARS-CoV-2 mutant, and raises the alarm that the ongoing vaccine development may become futile in future epidemic if more mutations were identified. ### Competing Interest Statement The authors have declared no competing interest."/>
  <meta name="og-title" property="og:title" content="Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of RBD mutant with lower ACE2 binding affinity"/>
  <meta name="og-url" property="og:url" content="https://www.biorxiv.org/content/10.1101/2020.04.09.034942v1"/>
  <meta name="og-site-name" property="og:site_name" content="bioRxiv"/>
  <meta name="og-description" property="og:description" content="Monitoring the mutation dynamics of SARS-CoV-2 is critical for the development of effective approaches to contain the pathogen. By analyzing 106 SARS-CoV-2 and 39 SARS genome sequences, we provided direct genetic evidence that SARS-CoV-2 has a much lower mutation rate than SARS. Minimum Evolution phylogeny analysis revealed the putative original status of SARS-CoV-2 and the early-stage spread history. The discrepant phylogenies for the spike protein and its receptor binding domain proved a previously reported structural rearrangement prior to the emergence of SARS-CoV-2. Despite that we found the spike glycoprotein of SARS-CoV-2 is particularly more conserved, we identified a mutation that leads to weaker receptor binding capability, which concerns a SARS-CoV-2 sample collected on 27th January 2020 from India. This represents the first report of a significant SARS-CoV-2 mutant, and raises the alarm that the ongoing vaccine development may become futile in future epidemic if more mutations were identified. ### Competing Interest Statement The authors have declared no competing interest."/>
  <meta name="og-type" property="og:type" content="article"/>
  <meta name="og-image" property="og:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="citation_date" content="2020-04-11"/> 
  <meta name="description" content="bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution"/>
  <meta name="generator" content="Drupal 7 (http://drupal.org)"/> 
  <title>Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of RBD mutant with lower ACE2 binding affinity | bioRxiv</title> 
 </head>
 <body class="html not-front not-logged-in page-node page-node- page-node-1239275 node-type-highwire-article context-content hw-default-jcode-biorxiv hw-article-category-new-results"> 
  <div class="article abstract-view ">
   <span class="highwire-journal-article-marker-start"/>
   <div class="section abstract" id="abstract-1">
    <h2>Abstract</h2>
    <p id="p-2">Monitoring the mutation dynamics of SARS-CoV-2 is critical for the development of effective approaches to contain the pathogen. By analyzing 106 SARS-CoV-2 and 39 SARS genome sequences, we provided direct genetic evidence that SARS-CoV-2 has a much lower mutation rate than SARS. Minimum Evolution phylogeny analysis revealed the putative original status of SARS-CoV-2 and the early-stage spread history. The discrepant phylogenies for the spike protein and its receptor binding domain proved a previously reported structural rearrangement prior to the emergence of SARS-CoV-2. Despite that we found the spike glycoprotein of SARS-CoV-2 is particularly more conserved, we identified a mutation that leads to weaker receptor binding capability, which concerns a SARS-CoV-2 sample collected on 27th January 2020 from India. This represents the first report of a significant SARS-CoV-2 mutant, and raises the alarm that the ongoing vaccine development may become futile in future epidemic if more mutations were identified.</p>
   </div>
   <h3>Competing Interest Statement</h3>
   <p id="p-3">The authors have declared no competing interest.</p>
   <span class="highwire-journal-article-marker-end"/>
  </div>
 </body>
</html>
